Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.

ASCO’s updated guidelines for advanced ovarian cancer emphasize health equity and provide new recommendations for HIPEC while ...

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Dogs of the Dow can be described as the 10 highest yielding stocks that are within the DJI. Read more to see the best Dog of ...

Glenmark Pharmaceuticals on Monday said it will pay USD 7 million to three entities to settle lawsuits in the US related to ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Glenmark Pharmaceuticals will pay USD 7 million to settle lawsuits in the US related to generic drugs, including Zetia and ...

Herbert Smith Freehills’ Priyanka Madan reports on a case involving a Merck SPC which was keenly anticipated by both ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.